InMed adds Johns Hopkins Alzheimer's expert Dr. Barry Greenberg to Scientific Advisory Board

InMed Pharmaceuticals Inc.

Dr. Greenberg is Director of Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine.
He has over four decades of Alzheimer's research and held leadership roles at AstraZeneca and Neurochem.
His expertise will guide InMed's INM-901 drug candidate toward human clinical trials for Alzheimer's disease.
He serves as Editor-in-Chief of 'Alzheimer's & Dementia: Translational Research and Clinical Interventions'.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.